Sign in or create an account to add this stock to your watchlist.
About Kindred Biosciences (NASDAQ:KIN)
Kindred Biosciences, Inc., a biopharmaceutical company, focuses on the development of therapies for pets. The company's product pipeline includes small molecules and biologics for a range of indications in dogs, cats, and horses. Its lead product candidates comprise Zimeta, a dipyrone injection for the control of pyrexia (fever) in horses; and Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats. The company's other small molecule product candidates consist of KIND-014 for treatment of equine gastric ulcers in horses; and KIND-015 for the management of clinical signs related to equine metabolic syndrome. It is also developing biologics programs, including KIND-510, a feline recombinant erythropoietin for the control of non-regenerative anemia in cats; KIND-011, an anti-tumor necrosis factor (TNF) to treat newborn foals; and canine atopic dermatitis, an immune-mediated inflammatory, chronic skin disease related to allergies. In addition, the company engages in the development of other biologic product candidates, such as KIND-502 to treat allergic and immune-mediated diseases; KIND-0888, an antibody that targets CD20; various antibodies that target cytokines involved in atopic dermatitis; KIND-509, an antibody that targets the canine TNF; and KIND-Bodies, a biologics scaffold technology. Further, it is developing anti-IL31, anti-IL17, and anti-IL4/13 sink antibodies for treating atopic dermatitis in dogs; anti-TNF antibody for inflammatory bowel disease in dogs; anti-IgE antibody for treating allergic diseases in dogs; anti-VEGF antibody for cancer in dogs; anti-CD20 for treating cancer and autoimmune diseases in dogs; and checkpoint inhibitors to treat cancer in dogs. Kindred Biosciences, Inc. was founded in 2012 and is headquartered in Burlingame, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KIN
CUSIPN/A
Phone650-701-7901
Debt
Debt-to-Equity RatioN/A
Current Ratio18.56
Quick Ratio18.56
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.70 per share
Price / Book3.65
Profitability
EPS (Most Recent Fiscal Year)($1.23)
Net Income$-30,870,000.00
Net MarginsN/A
Return on Equity-41.64%
Return on Assets-39.66%
Miscellaneous
Employees63
Outstanding Shares28,200,000
Kindred Biosciences (NASDAQ:KIN) Frequently Asked Questions
What is Kindred Biosciences' stock symbol?
Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."
How were Kindred Biosciences' earnings last quarter?
Kindred Biosciences (NASDAQ:KIN) posted its quarterly earnings data on Tuesday, May, 8th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.36). View Kindred Biosciences' Earnings History.
What price target have analysts set for KIN?
7 analysts have issued twelve-month price objectives for Kindred Biosciences' shares. Their predictions range from $10.50 to $16.75. On average, they expect Kindred Biosciences' share price to reach $12.5625 in the next year. View Analyst Ratings for Kindred Biosciences.
Who are some of Kindred Biosciences' key competitors?
Some companies that are related to Kindred Biosciences include Zai Lab (ZLAB), Alder BioPharmaceuticals (ALDR), Athenex (ATNX), TG Therapeutics (TGTX), Dynavax Technologies (DVAX), CytomX Therapeutics (CTMX), Esperion Therapeutics (ESPR), Eagle Pharmaceuticals (EGRX), Lexicon Pharmaceuticals (LXRX), Endocyte (ECYT), Flexion Therapeutics (FLXN), Omeros (OMER), MacroGenics (MGNX), OptiNose (OPTN) and Reata Pharmaceuticals (RETA).
Who are Kindred Biosciences' key executives?
Kindred Biosciences' management team includes the folowing people:
- Dr. Richard Chin, Co-Founder, Pres, CEO & Director (Age 51)
- Ms. Denise M. Bevers, Co-Founder, Chief Operating Officer and Sec. (Age 51)
- Ms. Wendy K. Wee, CFO & Principal Accounting Officer (Age 65)
- Dr. Hangjun Zhan, Chief Scientific Officer
- Dr. Noe Reyes D.V.M, Medical Director
Has Kindred Biosciences been receiving favorable news coverage?
News stories about KIN stock have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm scores the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Kindred Biosciences earned a daily sentiment score of 0.02 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 47.43 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
Who are Kindred Biosciences' major shareholders?
Kindred Biosciences' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Dimensional Fund Advisors LP (4.84%), BlackRock Inc. (3.91%), General American Investors Co. Inc. (2.12%), Wells Fargo & Company MN (1.28%), New York State Common Retirement Fund (0.86%) and B. Riley Financial Inc. (0.46%). Company insiders that own Kindred Biosciences stock include Park West Asset Management Llc, Raymond Townsend and Richard Chin. View Institutional Ownership Trends for Kindred Biosciences.
Which institutional investors are selling Kindred Biosciences stock?
KIN stock was sold by a variety of institutional investors in the last quarter, including Amtrust Financial Services Inc., General American Investors Co. Inc., BlackRock Inc. and Wells Fargo & Company MN. Company insiders that have sold Kindred Biosciences company stock in the last year include Raymond Townsend and Richard Chin. View Insider Buying and Selling for Kindred Biosciences.
Which institutional investors are buying Kindred Biosciences stock?
How do I buy shares of Kindred Biosciences?
Shares of KIN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Kindred Biosciences' stock price today?
One share of KIN stock can currently be purchased for approximately $9.85.
How big of a company is Kindred Biosciences?
Kindred Biosciences has a market capitalization of $280.62 million. The biopharmaceutical company earns $-30,870,000.00 in net income (profit) each year or ($1.23) on an earnings per share basis. Kindred Biosciences employs 63 workers across the globe.
How can I contact Kindred Biosciences?
Kindred Biosciences' mailing address is 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010. The biopharmaceutical company can be reached via phone at 650-701-7901 or via email at [email protected]
MarketBeat Community Rating for Kindred Biosciences (KIN)
MarketBeat's community ratings are surveys of what our community members think about Kindred Biosciences and other stocks. Vote "Outperform" if you believe KIN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KIN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Kindred Biosciences (NASDAQ:KIN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
7 Wall Street analysts have issued ratings and price targets for Kindred Biosciences in the last 12 months. Their average twelve-month price target is $12.5625, suggesting that the stock has a possible upside of 27.54%. The high price target for KIN is $16.75 and the low price target for KIN is $10.50. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.71 | 2.67 | 2.67 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
1 Strong Buy Rating(s) |
| Consensus Price Target: | $12.5625 | $10.10 | $9.90 | $9.80 |
| Price Target Upside: | 27.54% upside | 13.48% upside | 3.13% upside | 33.33% upside |
Kindred Biosciences (NASDAQ:KIN) Consensus Price Target History
Kindred Biosciences (NASDAQ:KIN) Analyst Ratings History
Show:
(Data available from 5/26/2016 forward)
Kindred Biosciences (NASDAQ:KIN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Kindred Biosciences (NASDAQ KIN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 15.96%
Institutional Ownership Percentage: 62.42%
Kindred Biosciences (NASDAQ KIN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/18/2018 | Richard Chin | Insider | Sell | 2,400 | $10.00 | $24,000.00 | 2,241,741 |  |
| 5/9/2018 | Richard Chin | Insider | Sell | 1,930 | $10.01 | $19,319.30 | 2,244,341 | |
| 5/7/2018 | Richard Chin | CEO | Sell | 1,730 | $10.01 | $17,317.30 | 2,244,341 | |
| 5/1/2018 | Richard Chin | Insider | Sell | 20,000 | $9.05 | $181,000.00 | 2,246,071 | |
| 4/2/2018 | Richard Chin | Insider | Sell | 20,000 | $8.39 | $167,800.00 | 2,266,071 | |
| 3/16/2018 | Raymond Townsend | Director | Sell | 2,670 | $9.45 | $25,231.50 | 25,057 | |
| 3/12/2018 | Raymond Townsend | Director | Sell | 91 | $9.45 | $859.95 | 23,233 | |
| 1/2/2018 | Raymond Townsend | Director | Sell | 6,419 | $9.45 | $60,659.55 | 18,419 | |
| 7/12/2017 | Park West Asset Management Llc | Major Shareholder | Buy | 600,000 | $7.50 | $4,500,000.00 | | |
| 7/3/2017 | Richard Chin | Insider | Sell | 13,000 | $8.26 | $107,380.00 | 2,297,546 | |
| 6/22/2017 | Richard Chin | Insider | Sell | 13,000 | $7.75 | $100,750.00 | 2,310,546 | |
| 6/8/2017 | Park West Asset Management Llc | Major Shareholder | Buy | 15,311 | $6.65 | $101,818.15 | | |
| 5/11/2017 | Park West Asset Management Llc | Major Shareholder | Buy | 155,076 | $6.83 | $1,059,169.08 | | |
| 3/15/2017 | Park West Asset Management Llc | Major Shareholder | Buy | 400,000 | $6.60 | $2,640,000.00 | | |
| 3/13/2017 | Park West Asset Management Llc | Major Shareholder | Buy | 4,200 | $6.20 | $26,040.00 | | |
| 3/9/2017 | Park West Asset Management Llc | Major Shareholder | Buy | 18,066 | $6.08 | $109,841.28 | | |
| 1/13/2017 | Park West Asset Management Llc | Major Shareholder | Buy | 1,690,000 | $6.20 | $10,478,000.00 | | |
| 1/9/2017 | Park West Asset Management Llc | Major Shareholder | Buy | 131,500 | $5.30 | $696,950.00 | | |
| 1/6/2017 | Park West Asset Management Llc | Major Shareholder | Buy | 110,617 | $5.10 | $564,146.70 | | |
| 12/16/2016 | Park West Asset Management Llc | Insider | Sell | 18,000 | $4.78 | $86,040.00 | | |
| 12/14/2016 | Park West Asset Management Llc | Major Shareholder | Buy | 8,334 | $4.75 | $39,586.50 | | |
| 12/13/2016 | Park West Asset Management Llc | Major Shareholder | Buy | 1,148 | $4.75 | $5,453.00 | | |
| 12/12/2016 | Park West Asset Management Llc | Major Shareholder | Buy | 3,112 | $4.74 | $14,750.88 | | |
| 3/15/2016 | Ernest Mario | Director | Buy | 30,000 | $3.55 | $106,500.00 | 99,583 | |
| 11/23/2015 | Raymond Townsend | Director | Buy | 2,000 | $4.00 | $8,000.00 | 12,000 | |
| 11/18/2015 | Raymond Townsend | Director | Buy | 2,323 | $4.78 | $11,103.94 | 10,000 | |
| 8/31/2015 | Raymond Townsend | Director | Buy | 1,677 | $5.85 | $9,810.45 | 7,677 | |
| 8/14/2015 | Raymond Townsend | Director | Buy | 3,000 | $6.04 | $18,120.00 | | |
| 9/29/2014 | Oleg Nodelman | Director | Buy | 100,000 | $9.56 | $956,000.00 | | |
| 9/3/2014 | Ernest Mario | Director | Buy | 10,000 | $10.55 | $105,500.00 | | |
| 8/28/2014 | Oleg Nodelman | Director | Buy | 47,000 | $10.85 | $509,950.00 | | |
| 8/26/2014 | Oleg Nodelman | Director | Buy | 85,244 | $10.50 | $895,062.00 | | |
| 12/12/2013 | Kevin Schultz | Insider | Buy | 4,000 | $7.00 | $28,000.00 | | |
| 12/12/2013 | Oleg Nodelman | Director | Buy | 400,000 | $7.00 | $2,800,000.00 | | |
| 12/12/2013 | Stephen Sundlof | SVP | Buy | 1,000 | $7.00 | $7,000.00 | | |
(Data available from 1/1/2013 forward)
Kindred Biosciences (NASDAQ KIN) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Kindred Biosciences (KIN) Now Covered by Analysts at EuroPacific Canada
www.americanbankingnews.com - May 23 at 4:19 PM |
| Kindred Biosciences (KIN) Insider Richard Chin Sells 2,400 Shares
www.americanbankingnews.com - May 18 at 8:53 PM |
| Zacks: Brokerages Expect Kindred Biosciences (KIN) Will Announce Earnings of -$0.39 Per Share
www.americanbankingnews.com - May 13 at 11:14 PM |
| Kindred Biosciences (KIN) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - May 12 at 10:39 AM |
 | Form 4 Kindred Biosciences, For: Feb 15 Filed by: Park West Asset Management LLC
www.streetinsider.com - May 12 at 10:23 AM |
 | Edited Transcript of KIN earnings conference call or presentation 8-May-18 8:30pm GMT
finance.yahoo.com - May 11 at 4:18 PM |
 | Kindred Biosciences' (KIN) CEO Richard Chin on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 11 at 10:42 AM |
| Q2 2018 EPS Estimates for Kindred Biosciences (KIN) Reduced by Analyst
www.americanbankingnews.com - May 11 at 9:41 AM |
| Kindred Biosciences Target of Unusually High Options Trading (KIN)
www.americanbankingnews.com - May 11 at 8:15 AM |
| Kindred Biosciences (KIN) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 10 at 7:37 PM |
| Unlocking The Value In Animal Medicine
finance.yahoo.com - May 10 at 9:53 AM |
| Kindred Biosciences (KIN) Releases Earnings Results, Meets Expectations
www.americanbankingnews.com - May 9 at 10:28 PM |
| Kindred Biosciences (KIN) CEO Richard Chin Sells 1,730 Shares
www.americanbankingnews.com - May 9 at 10:15 PM |
| Kindred Biosciences (KIN) Insider Richard Chin Sells 1,930 Shares
www.americanbankingnews.com - May 9 at 10:14 PM |
| Kindred Biosciences (KIN) Price Target Increased to $12.00 by Analysts at HC Wainwright
www.americanbankingnews.com - May 9 at 4:43 PM |
 | FDA Approves Kindred Bio’s Drug To Treat Weight Loss In Cats
www.bloomberg.com - May 9 at 4:20 PM |
 | BRIEF-Kindred Biosciences Reports Q1 Loss Per Share $0.36
www.reuters.com - May 9 at 9:42 AM |
| Blog Exposure - Kindred Biosciences Gets FDA Approval for Mirataz
finance.yahoo.com - May 9 at 9:42 AM |
| Kindred Biosciences Announces First Quarter 2018 Financial Results
finance.yahoo.com - May 8 at 4:18 PM |
| Is Prima Park SA. (WSE:KIN) A Financially Sound Company?
finance.yahoo.com - May 8 at 4:18 PM |
| This Peninsula company's new drug is the cat's meow — the FDA says so
finance.yahoo.com - May 8 at 9:35 AM |
| BRIEF-Kindred Biosciences Says Entered Into At Market Issuance Sales Agreement
www.reuters.com - May 7 at 9:29 AM |
| Form 424B5 Kindred Biosciences,
www.streetinsider.com - May 7 at 9:29 AM |
| Weight Gain Season for Felines
finance.yahoo.com - May 7 at 9:29 AM |
 | Kindred Biosciences Receives FDA Approval of Mirataz™ (mirtazapine transdermal ointment) for the Management of Weight Loss in Cats
www.prnewswire.com - May 7 at 7:12 AM |
| Kindred Biosciences (KIN) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - May 5 at 6:37 AM |
| Insider Selling: Kindred Biosciences (KIN) Insider Sells 20,000 Shares of Stock
www.americanbankingnews.com - May 2 at 10:30 PM |
| Kindred Biosciences (KIN) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - May 1 at 10:13 AM |
| Brokerages Expect Kindred Biosciences (KIN) Will Announce Earnings of -$0.38 Per Share
www.americanbankingnews.com - April 26 at 11:51 AM |
| Kindred Biosciences (KIN) Provides Updates on Pending Drug Approvals
www.streetinsider.com - April 25 at 4:28 PM |
| Kindred Biosciences Announces the Appointment of Dr. Ernest Mario and Dr. Joseph McCracken to its Board of Directors
finance.yahoo.com - April 25 at 4:28 PM |
| Kindred Biosciences Provides Updates on Pending Drug Approvals
finance.yahoo.com - April 24 at 4:30 PM |
| Kindred Biosciences to Announce First Quarter 2018 Financial Results
finance.yahoo.com - April 18 at 4:32 PM |
| Kindred Biosciences (KIN) Upgraded to "Buy" at ValuEngine
www.americanbankingnews.com - April 17 at 10:29 AM |
| Kindred Biosciences (KIN) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - April 15 at 7:31 PM |
| Kindred Biosciences (KIN) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - April 14 at 10:43 AM |
| Kindred Biosciences (KIN) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - April 13 at 1:35 PM |
| -$0.38 EPS Expected for Kindred Biosciences Inc (KIN) This Quarter
www.americanbankingnews.com - April 9 at 1:21 PM |
| Kindred Biosciences (KIN) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - April 9 at 12:10 PM |
| Kindred Biosciences (KIN) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - April 9 at 8:37 AM |
| Kindred Biosciences (KIN) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 7 at 2:14 PM |
| Richard Chin Sells 20,000 Shares of Kindred Biosciences Inc (KIN) Stock
www.americanbankingnews.com - April 4 at 11:16 PM |
| Kindred Biosciences (KIN) Downgraded by ValuEngine
www.americanbankingnews.com - March 31 at 12:42 PM |
| Kindred Biosciences (KIN) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - March 30 at 11:10 PM |
| Kindred Biosciences (KIN) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - March 24 at 10:54 AM |
| Kindred Biosciences Inc (KIN) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - March 21 at 7:36 PM |
| Kindred Biosciences Inc (KIN) Director Raymond Townsend Sells 2,670 Shares
www.americanbankingnews.com - March 19 at 8:30 PM |
| Kindred Biosciences to Present at the Oppenheimer 28th Annual Healthcare Conference
finance.yahoo.com - March 8 at 5:05 PM |
| Brokerages Expect Kindred Biosciences Inc (KIN) Will Announce Earnings of -$0.38 Per Share
www.americanbankingnews.com - March 6 at 9:43 AM |
| General American Investors Co. Inc. Sells 37,708 Shares of Kindred Biosciences Inc (KIN)
www.americanbankingnews.com - March 6 at 9:04 AM |
Kindred Biosciences (NASDAQ:KIN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Kindred Biosciences (NASDAQ:KIN) Income Statement, Balance Sheet and Cash Flow Statement
Kindred Biosciences (NASDAQ KIN) Stock Chart for Saturday, May, 26, 2018
Loading chart…
